A phase 2b, double-blind, randomized, placebo-controlled, parallel group, dose ranging study of oral PF-06651600 and PF-06700841 as induction and chronic therapy in subjects with moderate to severe uncerative colitis
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Developer: PFIZER INC.
- Phase: II
- Execution start: 26/09/2017
- End of execution: 30/09/2020
- IP: MARIA JOSE CABELLO TAPIA